Ranolazine 2 (CVT 3034)

Study of:
The main purpose of this study is to determine the long-term safety and tolerability of Ranolazine SR 500 mg twice a day, 750 mg twice a day and 1000 mg twice a day administered in combination with other anti-anginal therapy(ies) in patients with chronic stable angina during an open-label treatment period of up to approximately 8 years duration. The secondary objective is to assess the long-term safety and tolerability of Ranolazine SR 500 mg twice a day, 750 mg twice a day and 1000 mg twice a day on patients who have reduced or discontinued concomitant anti-anginal medication(s).

For more information about this study or other research studies at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Terri Streufert at 612-863-7821.